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Fulminant hepatic failure (FHF) is a clinical syndrome characterized by sudden and
severe impairment of liver function. Mesenchymal stem cells (MSCs) have been pro-
posed as a promising therapeutic approach for FHF. In this study we used Propionibac-
terium acnes (P. acnes)-primed, lipopolysaccharide (LPS)-induced liver injury in mice
as an animal model of human FHF. We demonstrated that administration of MSCs sig-
nificantly ameliorated liver injury and improved the survival rates of mice subjected to
P. acnes plus LPS-induced FHF. Allogeneic MSCs showed similar treatment efficacy as
autologous MSCs did in FHF. Treatment efficacy of MSCs could be attributed to
decreased infiltration and activation of CD41 T cells in the liver, inhibition of T helper
1 cells, and induction of regulatory T cells (Tregs). Moreover, decreased DNA copies of
P. acnes were detected in the liver of MSC-treated mice. Intriguingly, a distinct liver
population of CD11c1MHCIIhiCD80loCD86lo regulatory dendritic cells (DCs) was
induced by MSCs. Moreover, these DCs induced Treg differentiation through transform-
ing growth factor-b production. Further mechanistic studies demonstrated that MSC-
derived prostaglandin E2 and one of its receptors, EP4, played essential roles in the dif-
ferentiation of CD11c1B2202 DC precursors into regulatory DCs in a phosphoinosi-
tide 3-kinase-dependent manner. Conclusion: MSCs induce regulatory DCs from
CD11c1B2202 DC precursors. This study elucidates an immunoregulatory mechanism
of MSCs and lays a foundation for application of MSCs in FHF therapy. (HEPATOLOGY
2014;59:671-682)
F
ulminant hepatic failure (FHF), which develops
secondary to infection, toxin, or immune-
mediated attack, is a potentially fatal clinical
syndrome characterized by rapid development of hepa-
tocellular dysfunction, especially coagulopathy with
diffuse intrahepatic infiltration of inflammatory cells
and massive multilobular necrosis.1,2 The mechanisms
leading to such profound hepatic damage are not fully
understood. Inflammatory responses are involved in
the pathophysiology of hepatic cell death and liver
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injury and are associated with failure of hepatic regen-
eration.3 Mortality without supportive management or
liver transplantation is high. Orthotopic liver trans-
plantation is the current gold standard of care, but its
use is limited because of organ donor shortage, finan-
cial considerations, and the requirement for lifelong
immunosuppression.4
Mesenchymal stem cells (MSCs) of multiple origins
can differentiate into osteocytes, chondrocytes, adipo-
cytes, neuron-like cells, and hepatocyte-like cells.5 In
addition to their wide use in regeneration therapy, the
unique immunologic characteristics of MSCs, such as
low immunogenicity and immunoregulatory properties,
have attracted increased attention.5 MSCs mediate a sys-
temic immunosuppression and have been tested in the
treatment of immune disorders such as experimental
autoimmune encephalomyelitis, rheumatoid arthritis,
and diabetes in several preclinical and clinical studies.5-7
Various mediators are proposed to be responsible for the
immunosuppressive capacity of MSCs, such as trans-
forming growth factor (TGF)-b, indoleamine 2,3-dioxy-
genase, inducible nitric oxide synthase (iNOS), and
prostaglandin E2 (PGE2).
8 As such, these properties
have suggested great therapeutic potential for MSCs in
the context of cell-based therapy. Recently, several stud-
ies reported that MSCs could relieve liver fibrosis and
promote liver regeneration.9 Whether MSCs are effec-
tive in the treatment of FHF and the underlying immu-
noregulatory mechanisms remain elusive.
Dendritic cells (DCs) are the most potent, profes-
sional antigen-presenting cells derived from CD341
hematopoietic progenitor cells (HPCs). DCs are key
mediators for the initiation and regulation of both
innate and adaptive immune responses. In contrast to
the well-known capacity of conventional DCs to prime
T cells effectively, regulatory DCs serve to induce
immune tolerance and have been used successfully to
prevent the onset of delayed-type hypersensitivity, coli-
tis, and collagen-induced arthritis.10 Recently, several
groups reported that MSCs may drive the differentia-
tion of regulatory DCs from HPCs.11,12 However, the
underlying mechanisms are still poorly understood and
the induction of regulatory DCs in vivo remains
controversial.
Priming of mice with heat-killed Propionibacterium
acnes (P. acnes) followed by a low dose of lipopolysac-
charide (LPS) results in acute liver injury in mice, and
is one of the commonly used animal models mimicking
FHF in humans. In this model, liver injury is patho-
physiologically classified into two phases.1,13-16 In the
priming phase, as we previously reported,
CD11c1B2202 DC precursors are mobilized rapidly
into the circulation in mice injected with P. acnes.14,15
This is an initial event and a prerequisite for liver injury
in this model. Then, DC precursors are recruited into
inflammatory liver tissue and differentiate into mature
DCs, activating P. acnes-specific CD41 T cells in the
hepatic lymph nodes, which are then recruited to the
liver.15 The accumulation of these mononuclear cells
(MNCs) in the liver leads to granuloma formation.1,16
In the eliciting phase, LPS injection further increases
liver inflammation, leading to massive hepatic cell death
and rapid liver failure.16 Therefore, inhibition of
inflammatory infiltration and immune responses evoked
by DCs is beneficial for treatment of the disease.
In this study, using P. acnes-primed, LPS-induced FHF
in mice, we found that MSC treatment effectively attenu-
ated the severity of liver injury in mice and reduced mor-
tality of FHF through inhibiting T helper (Th) 1 cells
and induction of regulatory T cells (Tregs). More impor-
tant, we demonstrate that MSCs ameliorated clinical
symptoms and disease progression by secretion of PGE2,
which induced the differentiation of liver regulatory DCs
from CD11c1B2202 DC precursors by activating
EP4 and the associated phosphoinositide 3-kinase
(PI3K)/extracellular signal-regulated kinase (ERK) 1/2
signaling pathway.
Materials and Methods
Induction of Liver Injury. C57BL/6 mice were
primed intravenously with 1 mg of heat-killed P. acnes.
For survival analysis, mice were injected intravenously
with 1 lg of LPS on day 7 after P. acnes priming. For
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the indicated experiments, a total of 1 3 106 MSCs
or vehicle was injected intravenously on days 0, 2, and
4 (a prophylactic protocol), or on days 3, 5, and 7 (a
therapeutic protocol for granulomatous hepatitis). In
some MSC-treated mice, NS398 (500 lg/mouse),
NG-monomethyl-L-arginine acetate salt (L-NMMA;
500 lg/mouse) (both from Sigma-Aldrich, St. Louis,
MO), or vehicle was administered intraperitoneally
daily from day 0 until day 6.
Induction of DC Maturation. Mature DCs were
generated from CD11c1B2202 DC precursors as pre-
viously described with some modifications.14 In brief,
purified CD11c1B2202 cells were cultured in the
presence of granulocyte-macrophage colony-stimulating
factor (GM-CSF; 10 ng/mL) and interleukin (IL)-4 (5
ng/mL) (both from PeproTech, Rocky Hill, NJ) for 5
days to induce immature DCs (immature DC induc-
tion phase). Cells were further incubated with GM-
CSF and tumor necrosis factor (TNF)-a (50 ng/mL;
PeproTech) on type I collagen-coated plates for 3 more
days to induce mature DCs (mature DC induction
phase).
Histology and immunofluorescence, flow cytometric
analysis, DC precursor-MSC cocultures, quantitative
real-time polymerase chain reaction (PCR), western
blot, and all other materials and methods are described
in the Supporting Information.
Results
MSCs Ameliorate the Severity of Bacteria-Induced
Liver Injury and Reduce the Mortality of FHF. To
determine the efficacy of MSCs in FHF, MSCs from
C57BL/6 mice or vehicle was injected intravenously
after P. acnes priming. For the vehicle-treated group,
all C57BL/6 mice died within 18 hours post-LPS
injection. By contrast, MSC treatment with either a
prophylactic protocol or a therapeutic protocol for
granulomatous hepatitis effectively improved the sur-
vival rate of FHF, and all mice survived more than 7
days post-LPS injection (Fig. 1A; Supporting Fig.
S1A). These were consistent with a dramatic decrease
in alanine aminotransferase (ALT) and aspartate ami-
notransferase (AST) levels in the serum of MSC-
treated mice (Fig. 1B; Supporting Fig. S1B). Histology
showed that large nodules, severe infiltration of lym-
phocytes, and granuloma formation were observed in
liver tissues on day 7 post-P. acnes priming, liver
weight increased considerably (Fig. 1C; Supporting
Figs. S1C, S2A,B). Moreover, Fas ligand expression
was also elevated (Fig. 1D). By contrast, livers isolated
from mice treated with MSCs displayed normal mor-
phology without nodules, much less infiltration of
lymphocytes, markedly reduced granulomas, normal
weight, and remarkably reduced Fas ligand expression
Fig. 1. MSCs ameliorate the severity of bacteria-induced liver injury. Mice were injected with P. acnes (P.ac) suspended in 100 lL of
phosphate-buffered saline (PBS). PBS or MSCs were administered intravenously on days 0, 2, and 4, and 1 lg of LPS in 100 lL of PBS was
injected on day 7 to induce FHF. (A) Cumulative survival rates of mice were analyzed. Data from two independent experiments are combined (n
5 10 mice per group). (B-D) Serum and liver tissues from naive, PBS, or MSC-treated mice were sampled on day 7 after P. acnes priming.
Serum levels of ALT and AST (B; n 5 8 mice per group), and mRNA level of Fas ligand in livers (D; n 5 6 mice per group) were measured.
Results are mean 6 SEM from three independent experiments. (C) Liver tissues were sectioned for histological examination. Scale bar 5 100
lm. Representative images from one experiment out of three are shown. **P < 0.01.
HEPATOLOGY, Vol. 59, No. 2, 2014 ZHANG, CAI, ET AL. 673
(Fig. 1C,D; Supporting Figs. S1C, S2A,B). Impor-
tantly, MSCs from BALB/c mice also ameliorated
FHF in C57BL/6 mice (Supporting Fig. S3A,B).
Taken together, these data demonstrate that MSC
treatment effectively attenuated the severity of
bacteria-induced liver injury and improved the sur-
vival rate of FHF. Interestingly, MSCs were effica-
cious in amelioration of concanavalin A (ConA)-
induced acute liver injury as evidenced by signifi-
cantly decreased serum levels of ALT and AST,
reduced areas of focal necrosis, and less lymphocyte
infiltration around the central veins in the liver com-
pared to those of controls (Supporting Fig. S4A,B).
Additionally, we also investigated the in vivo tumori-
genesis of MSCs and no tumor was detected in mice
inoculated with MSCs during a period of 1 month
observation (Supporting Fig. S5).
MSCs Reduce Migration and Activation of CD41
T Cells in the Liver. It is known that T-cell-mediated
inflammation plays an important role in P. acnes-
induced liver injury.15 MNCs accumulated significantly
in the liver of P. acnes-primed control mice, and both
the percentage and absolute number of CD41 T cells
increased dramatically in the liver (Fig. 2A,B). However,
fewer CD41 T cells were detected in the spleen (Fig.
2A). Intriguingly, infiltration of MNCs and CD41 T
cells decreased significantly in the liver of MSC-treated
mice, while CD41 T cells in the spleen remained at
levels similar to those of naive mice (Fig. 2A,B).
Accordingly, expression of CXCR3, CCR5, and CCR7
on CD41 T cells and their respective chemokines
CXCL9, CXCL10, CCL3, and CCL21 in the liver of
MSC-treated mice were reduced considerably (Fig.
2C,D). These results indicated that MSC treatment
Fig. 2. MSCs reduce migration and activation of CD41 T cell in the liver. Mice were injected with P. acnes (P.ac). PBS or MSCs were adminis-
tered intravenously on days 0, 2, and 4 after P. acnes injection. Livers or spleens were isolated from naive, PBS, or MSC-treated mice on day 7.
(A) Absolute numbers of total MNCs, percentages and absolute numbers of CD41 T cells in these tissues were determined by flow cytometry.
(B) Immunofluorescence staining of CD41 T cells in liver tissues. Scale bar 5 100 lm. Representative images from one experiment out of three
are shown. (C) Levels of CXCR3, CCR5, and CCR7 on CD41 T cells derived from livers were analyzed by flow cytometry. (D) mRNA levels of che-
mokines in livers were measured by quantitative real-time PCR. (E) Levels of CD44, CD62L, CD69, and CD25 on CD41 T cells of livers and
spleens were analyzed by flow cytometry. (A,D) Results are mean 6 SEM from three independent experiments (n 5 6 mice per group). (C,E)
Gray shading and solid line indicate immunofluorescence intensity of cells for the control and test antibodies, respectively. Results are represen-
tative of three independent experiments. *P < 0.05; **P < 0.01.
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suppressed the chemotaxis of pathogenic CD41 T cells
into the liver. In addition, MSC-treated mice showed
decreased expression of CD44 and CD69 and increased
expression of CD62L (Fig. 2E), suggesting that MSCs
suppressed CD41 T-cell activation in the mice.
MSCs Suppress Th1 Cells but Promote Tregs in
the Liver. We previously identified Th1 cells as cen-
tral players in the pathogenesis of P. acnes-induced liver
injury.1 Thus, serum levels of Th1 cytokines TNF-a
and interferon (IFN)-c, Th2 cytokines IL-4 and IL-5,
and another proinflammatory cytokine IL-17, were
determined. As shown in Fig. 3A, MSCs reduced lev-
els of TNF-a and IFN-c significantly, but had no
effect on IL-4, IL-5, or IL-17 production. Intracellular
staining of TNF-a and IFN-c further confirmed the
reduction of TNF-a- and IFN-c-positive cells within
CD41 T cells (Fig. 3B). By contrast, administration
of MSCs significantly increased CD41CD251Foxp31
Tregs as compared with the vehicle treatment (Fig.
3C). These data demonstrate that MSCs suppressed
Th1 cells but promoted Tregs in the liver. Interest-
ingly, MSC treatment accelerated elimination of the
bacteria, since DNA copies of P. acnes 16S rDNA in
the liver of MSC-treated mice were considerably lower
from day 1 post-P. acnes priming onwards as compared
to those of controls (Supporting Fig. S6A). In addi-
tion, MSC-treated mice showed significantly reduced
lymphocyte infiltration in the liver, and marked
decrease in serum levels of AST, ALT, TNF-a, and
IFN-c on day 28 post-P. acnes priming (Supporting
Fig. S6B-D). Taken together, the data suggest that
transfer of MSCs down-regulated excessive Th1
response but retained the T-cell response controlling
the bacteria in vivo.
Fig. 3. MSCs suppress Th1 cells but
promote Tregs in the liver. Mice were
injected with P. acnes (P.ac). PBS or
MSCs were administered intravenously
on days 0, 2, and 4 after P. acnes
injection. Peripheral blood, livers, or
spleens were isolated from naive, PBS,
or MSC-treated mice on day 7. (A) Lev-
els of serum IFN-c, TNF-a, IL-4, IL-5,
and IL-17 were measured by cytometric
bead array or enzyme-linked immuno-
sorbent assay. Data are mean 6 SEM
from three independent experiments
(n > 6 mice per group). (B) Inflamma-
tory cytokine production in CD41 T
cells were assessed by intracellular
staining and flow cytometry. Gray shad-
ing and solid line indicate immunofluo-
rescence intensity of cells for the
control and test antibodies, respec-
tively. Data are representative of three
independent experiments. (C) MNCs
isolated from livers and spleens were
stained for surface markers and intra-
cellular expression of Foxp3 and ana-
lyzed by flow cytometry. Representative
dot plots are shown on the left and
summarized results are shown as mean
6 SEM from three independent experi-
ments (n 5 6 mice per group) on the
right. *P < 0.05; **P < 0.01.
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Distinct Regulatory DC Population Is Induced by
MSC Treatment. In the P. acnes-induced liver injury
model, antigen-presenting cells, such as Kupffer cells
and DCs, elicit inflammatory responses by presenting
antigens to CD41 T cells. The DC-T cell interactions
are then amplified by continuous stimulation of
recruited DCs to liver-infiltrating CD41 T cells,
resulting in subsequent liver injury.13 In this regard,
we investigated whether MSC treatment could influ-
ence activation and function of antigen-presenting cells
in the liver. MSC treatment did not affect the expres-
sion of MHC class II (MHCII) and costimulatory
molecules (e.g., CD80 and CD86) in F4/801 Kupffer
cells, but dramatically reduced CD80 and CD86
expression in CD11c1 DCs and increased their
MHCII expression level (Fig. 4A). In addition, these
DCs displayed the same phenotype after further stimu-
lation with GM-CSF and TNF-a in vitro (Fig. 4B).
They were defined as MSC-DCs thereafter. In a func-
tional study, these MSC-DCs showed a much lower
capability to evoke an allogeneic mixed lymphocyte
reaction (MLR) as compared with DCs isolated from
control mice (cont-DCs) (Fig. 4C), although these
DCs could uptake more FITC-dextran than cont-DCs
(Fig. 4D). In addition, MSC-DCs produced lower lev-
els of proinflammatory cytokines including TNF-a,
IL-1b, and IL-12 than cont-DCs (Fig. 4E). These data
suggested that these MSC-DCs were distinct from
either immature or mature conventional DCs. Further-
more, MSC-DCs significantly suppressed allogeneic
CD41 T cell proliferation elicited by cont-DCs in a
dose-dependent manner (Fig. 5A). Interestingly, MSC-
DCs, but not cont-DCs, were able to induce Tregs
efficiently when cocultured with naive T cells (Fig.
5B). Notably, MSCs from BALB/c mice were also able
to induce MSC-DCs in C57BL/6 mice (Supporting
Fig. 4. MSCs induce a distinct population of regulatory DCs. Mice were injected with P. acnes (P.ac). PBS or MSCs were administered intrave-
nously on days 0, 2, and 4 after P. acnes injection. Livers were isolated from naive, PBS, or MSC-treated mice on day 7. (A) Levels of MHCII,
CD80, and CD86 on F4/801 Kupffer cells or CD11c1 DCs of livers were analyzed by flow cytometry. (B) Immature DCs induced from
CD11c1B2202 DC precursors of PBS-treated mice or MSC-DCs magnetically purified from liver MNCs of MSC-treated mice were stimulated with
GM-CSF (10 ng/mL) and TNF-a (50 ng/mL) for 3 days in vitro. The phenotypes of both types of cells before and after stimulation were analyzed
by flow cytometry. (C) Cont-DCs or MSC-DCs were magnetically purified from liver MNCs of C57BL/6 mice. After lethally irradiated (30 Gy), they
were cultured in graded doses with magnetically purified CD41 T cells (3 3 105 cells/well) from the spleen of naive BALB/c mice. Five days
later, T-cell proliferation was measured by incorporation of [3H]thymidine. Data are mean 6 SEM (n 5 3). (D) Cont-DCs or MSC-DCs were incu-
bated with FITC-dextran (0.5 mg/mL) at 4C or 37C for 120 minutes. The capacity of antigen uptake was detected by measuring the mean flu-
orescence intensities (MFI) of the fraction of FITC-positive cells using flow cytometry. Representative histograms are shown on the left and
summarized results are shown as mean 6 SEM (n 5 6). (E) Collected cont-DCs or MSC-DCs were cultured with GM-CSF (10 ng/mL) in vitro.
After 3 days, levels of TNF-a, IL-1b, and IL-12 in supernatants were measured by enzyme-linked immunosorbent assay. Results are mean 6
SEM (n 5 6). (A,B) Gray shading and solid line indicate immunofluorescence intensity of cells for the control and test antibodies, respectively.
Data are representative of three independent experiments. *P < 0.05; **P < 0.01.
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Fig. S3C-E). In vivo studies were then performed to
validate the immunoregulatory functions of MSC-
DCs. MSC-DC treatment effectively improved mice
survival rate of FHF, as compared with cont-DCs, by
inducing the generation of Tregs (Fig. 5C,D).
Besides, transfer of MSC-DCs significantly decreased
serum levels of ALT and AST, and reduced lympho-
cyte infiltration in the liver compared to those of
cont-DCs (Supporting Fig. S7A,B). Altogether, these
data demonstrated that these CD11c1MHCIIhiC-
D80loCD86lo MSC-DCs resemble the regulatory DC
population, but are distinct from conventional stimu-
latory DCs.
MSC-DCs Suppress T-Cell Immune Responses and
Induce Treg Differentiation Through Production of
TGF-b. Besides the expression of low levels of costi-
mulatory molecules, MSC-DCs may execute their sup-
pressive functions through expression of a group of
inhibitory molecules such as CD200R3, Aldh1a (a gene
involved in retinoid acid metabolism), IL-10, and TGF-
b (Supporting Table 1).17,18 Among them, we found
that messenger RNA (mRNA) levels of TGF-b and IL-
10 were remarkably elevated in MSC-DCs as compared
with those of cont-DCs (Fig. 5E; Supporting Fig. S8).
Accordingly, MSC-DCs secreted more TGF-b and
IL-10 than cont-DCs (Fig. 5F). We then evaluated the
Fig. 5. Immunoregulatory function of liver MSC-DCs. Mice were injected with P. acnes (P.ac). PBS or MSCs were administered intravenously on
days 0, 2, and 4 after P. acnes injection. Livers or spleens were isolated from PBS or MSC-treated mice on day 7. (A) CD41 T cells (3 3 105
cells/well) from the spleen of naive BALB/c mice were incubated with or without lethally irradiated (30 Gy) cont-DCs (3 3 104 cells/well) from
C57BL/6 mice. In the indicated experiments, MSC-DCs from C57BL/6 mice were added to the coculture system in graded doses. Five days
later, T-cell proliferation in response to the indicated treatments was measured by incorporation of [3H]thymidine. Data are mean 6 SEM from
three independent experiments (n 5 3). (B) CD41CD252 T cells from C57BL/6 mice were cultured with syngeneic cont-DCs or MSC-DCs in the
presence of plate-coated anti-CD3 antibody (5 lg/mL) and soluble anti-CD28 antibody (2 lg/mL). In the indicated experiments, anti-TGF-b,
anti-IL-10 neutralizing antibody (a-TGF-b or a-IL-10), or control IgG was added into the culture system, respectively. Five days later, cells were
stained for surface markers and intracellular expression of Foxp3, and analyzed by flow cytometry. (C,D) C57BL/6 mice were infused intrave-
nously with 5 3 105 cont-DCs or MSC-DCs on days 2 and 4 after P. acnes priming. In some experiments, mice infused with MSC-DCs were also
treated with anti-TGF-b, anti-IL-10 neutralizing antibody, or control IgG (7 mg/kg). LPS was injected on day 7, and cumulative survival rates were
analyzed. Data from two independent experiments are combined (C; n 5 10 mice per group). (D) MNCs isolated from livers or spleens were
stained for surface markers and intracellular expression of Foxp3, and analyzed by flow cytometry. (E) mRNA levels of TGF-b and IL-10 in cont-
DCs and MSC-DCs were measured by quantitative real-time PCR. Data are normalized to expression levels of cont-DCs. (F) Collected cont-DCs
or MSC-DCs were cultured with GM-CSF (10 ng/mL) in vitro. After 3 days, levels of TGF-b and IL-10 in supernatants were measured by enzyme-
linked immunosorbent assay. (B,D) Representative dot plots are shown on the bottom and summarized results are mean 6 SEM from three inde-
pendent experiments (n 5 6 mice per group) on the top. (E,F) Results are mean 6 SEM (n 5 6). *P < 0.05; **P < 0.01.
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function of TGF-b and IL-10 in MSC-DC-mediated
Treg differentiation. As shown in Fig. 5B, anti-TGF-b
neutralizing antibody significantly reversed Treg induc-
tion by MSCs; anti-IL-10 neutralizing antibody also
blocked Treg differentiation but to a much less extent.
Moreover, in vivo experiments also provided evidence
demonstrating that MSC-DCs could induce Treg gener-
ation, an effect significantly blocked by infusion of anti-
TGF-b neutralizing antibody and partially blocked by
anti-IL-10 neutralizing antibody (Fig. 5C,D). These
data demonstrate that TGF-b played an important role
in MSC-DC-mediated Treg differentiation.
MSCs Induce Differentiation of CD11c1B2202
DC Precursors Into Regulatory DCs. Our previous
studies showed that after P. acnes priming, circulating
CD11c1B2202 DC precursors could be mobilized to
the liver and gradually differentiate into functional,
mature DCs to elicit immune responses.14 Thus, we set
out to determine whether MSCs altered the characteris-
tics of DC precursors. The number of DC precursors
in periphery blood increased markedly and peaked on
day 7 post-P. acnes priming to a similar level in vehicle
and MSC-treated groups (Fig. 6A). In addition, DC
precursors from both groups displayed a similar capabil-
ity to differentiate into conventional, mature DCs (Fig.
6B), suggesting that MSC treatment did not influence
recruitment of DC precursors into the periphery blood
or their potential to differentiate into mature DCs.
To further dissect the cellular mechanisms involved
in regulatory DC induction by MSCs, peripheral DC
precursors, derived from P. acnes-primed mice, were
cultured to induce immature DCs, and then fully
mature DCs. MSCs were added into the culture either
during the immature DC induction phase, mature DC
induction phase, or both phases. Compared with the
high expression of MHCII, CD80, CD86, and
DEC205 in the control group, culture with MSCs for
8 days induced a regulatory DC phenotype; the cells
displayed higher expression of MHCII, but decreased
expression of CD80, CD86, and DEC205 (Fig. 6C).
Interestingly, culture with MSCs during the immature
DC induction phase, but not during the mature DC
induction phase, resulted in the typical phenotype of
regulatory DCs (Fig. 6C). Furthermore, functional
studies indicated that, phenotypically, regulatory DCs
could not elicit allogeneic CD41 T-cell proliferation,
but indeed significantly suppress allogeneic CD41 T-
cell proliferation elicited by DCs treated with MSCs
only during the mature DC induction phase (Fig.
6D). These results indicated that regulatory DCs could
be induced from CD11c1B2202 DC precursors by
MSC treatment in vitro.
MSC-Derived PGE2 Plays an Essential Role in
the Induction of Regulatory DCs From DC Precur-
sors by Activating the PI3K/ERK1/2 Path-
way. PGE2 and iNOS are important effectors derived
from MSCs. Thus, we evaluated whether PGE2 or
iNOS participated in the induction of regulatory DCs.
The PGE2-specific inhibitor NS398, but not the iNOS
inhibitor L-NMMA, significantly blocked the differen-
tiation of regulatory DCs from DC precursors as well
as the suppressive function of regulatory DCs (Fig.
6C,D). Furthermore, an in vivo study showed that inhi-
bition of PGE2 significantly reversed the treatment
effect of MSCs on P. acnes plus LPS-induced FHF (Fig.
6E). Altogether, these results indicated that MSC-
derived PGE2 was essential for the differentiation of
CD11c1B2202 DC precursors into regulatory DCs.
To further explore the molecular mechanisms
involved in differentiation of regulatory DCs, we
assayed phosphorylation of PI3K and ERK1/2 as acti-
vation indicator in MSC-induced regulatory DCs.
PI3K and ERK1/2 are known signaling downstream
kinases following binding of PGE2 and its respective
receptors, EP2 and EP4.19,20 Markedly elevated phos-
phorylation of PI3K and ERK1/2 was detected in
CD11c1B2202 cells after coculture with MSCs. Intri-
guingly, NS398 as well as the EP4 antagonist
AH23848 markedly inhibited phosphorylation of
PI3K and ERK1/2, whereas AH6809, an EP2 antago-
nist, did not affect the activation of these proteins
(Fig. 6F). Thus, MSC-derived PGE2 plays an essential
role in the induction of regulatory DCs from DC pre-
cursors by activating EP4 and associated PI3K/ERK1/
2 signaling pathway.
Discussion
Our findings demonstrate that MSCs effectively
attenuate the severity of bacteria-induced liver injury and
increase survival rate of mice subjected to P. acnes plus
LPS-induced FHF. Mechanistically, MSCs induce differ-
entiation of a distinct, functional CD11c1MHCIIhi
CD80loCD86lo regulatory DC population from
CD11c1B2202 DC precursors through production of
PGE2 in a PI3K-dependent manner. These regulatory
DCs inhibit Th1 cells and induce Tregs, resulting in
amelioration of FHF.
MSCs can differentiate in vitro along the hepato-
genic lineage, and have been extensively investigated as
potential sources for liver regeneration.21 In the cur-
rent study, we focused on dissecting the underlying
immunoregulatory mechanisms for application of
MSCs in FHF treatment. We provide clear evidence
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that delivery of MSCs dramatically decreases mortality
and alleviates liver injury. Detailed analyses demon-
strated that MSCs induced a distinct DC population
characterized by a CD11c1MHCIIhiCD80loCD86lo
phenotype with potent regulatory function. These
DCs were able to phagocytose antigens efficiently but
could not present the antigens properly due to their
insufficient expression of CD80 and CD86. In
addition, MSC-DCs produced low levels of proinflam-
matory cytokines including TNF-a, IL-1b, and IL-12,
and were defective in stimulating proliferation of allo-
geneic T cells in MLR cultures, but were able to sup-
press T-cell proliferation and induce Tregs. These
findings are reminiscent of a recent study, which
showed that a population of regulatory DCs expressed
the phenotype of MHCIIhiCD80loCD86lo and pos-
sessed potent ability to repress inflammatory T-cell
responses.22 Conventional mature DCs express high
levels of antigen-presenting molecules (e.g., MHCII)
and costimulatory molecules, produce large amounts
Fig. 6. PGE2 secreted by MSCs is essential for the generation of regulatory DCs. Mice were injected with P. acnes (P.ac). PBS or MSCs were
administered intravenously three times on days 0, 2, and 4 after P. acnes injection. (A) Periphery blood of PBS or MSC-treated mice was col-
lected on days 1, 3, 5, or 7. CD11c1B2202 DC precursors were analyzed by flow cytometry. Data are shown as mean 6 SEM from three inde-
pendent experiments (n 5 6). (B) Purified DC precursors from PBS or MSC-treated mice blood on day 7 were sorted out and incubated with
GM-CSF (10 ng/mL) plus IL-4 (5 ng/mL) for 5 days and GM-CSF plus TNF-a (50 ng/mL) for 3 more days. Cells collected on day 8 were stained
for MHCII, CD80, CD86, and DEC205 and analyzed by flow cytometry. (C) Induction of mature DCs from DC precursors was performed as
described in (B). In the indicated experiments, MSCs were included in the culture during the immature DC induction phase (d1-d5), mature DC
induction phase (d6-d8), or both phases (d1-d8). In some experiments with MSC treatment, NS398 (5 lM), L-NMMA (1 mM), or DMSO was
added to the culture. Cells were stained for MHCII, CD80, CD86, and DEC205, and analyzed by flow cytometry. (D) Induction of DCs from DC
precursors was performed as described in (B,C). DCs induced from DC precursors in the presence of MSCs during various phases were indicated
as DC(d1-d5), DC(d6-d8), or DC(d1-d8), respectively. For those cocultured with MSCs during d1-d5, NS398, L-NMMA, or DMSO was also
included in the culture. Then, DCs were sorted out and cultured with CD41 T cells derived from BALB/c mice as indicated. Five days later, T-cell
proliferation was measured by incorporation of [3H]thymidine. Data are mean 6 SEM (n 5 3). (E) P. acnes-primed mice were intravenously
injected with PBS or MSCs. Those treated with MSCs were subsequently injected with nothing, NS398 (500 lg/mouse), L-NMMA (500 lg/
mouse), or DMSO. All animals were then injected with LPS and survival rates were followed for 24 hours. Data from two independent experi-
ments are combined (n 5 10 mice per group). (F) Purified DC precursors were incubated with GM-CSF and IL-4, with or without MSCs. In some
experiments, NS398, AH23848, AH6809, or DMSO was added to the culture system. After 48 hours, levels of p-PI3K, p-ERK1/2, ERK1/2, and
vinculin from cultured cells were determined by western blot analysis. (B,C,F) Results are representative of three independent experiments. *P <
0.05; **P < 0.01.
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of proinflammatory cytokines (e.g., TNF-a, IL-1b,
and IL-12), have great ability to stimulate proliferation
and expansion of allogeneic T cells in a MLR culture.
However, the immature DCs are characterized by low
T-cell activation potential accompanied by low expres-
sion of MHCII and costimulatory molecules. Upon
inflammatory stimulation, immature DCs are able to
acquire both phenotypic and functional properties of
mature DCs.23,24 Notably, despite in vitro stimulation
with GM-CSF plus TNF-a for 3 days, which has been
shown to effectively induce maturation of conventional
immature DCs,14 MSC-DCs fail to up-regulate the
expression of CD80 and CD86. Taken together, these
observations suggest that MSC-DCs resemble to regu-
latory DCs, but are distinct from either immature or
mature conventional DCs which can elicit primary T-
cell responses. Thus, it is likely the active phagocytosis
may represent a unique property of MSC-DCs rather
than maturity conditions. In fact, various regulatory
DC populations have been identified in distinct set-
tings during the last years,22,23,25-27 which support the
concept of significant heterogeneity of regulatory DC
populations.
Regulatory DCs comprise a heterogeneous popula-
tion located in various tissues, where they use distinct
mechanisms to induce and maintain central and periph-
eral tolerance. In the current study, we found MSC-
DCs highly express TGF-b and IL-10 as compared
with cont-DCs. Moreover, these MSC-DCs induce Treg
differentiation in a TGF-b-dependent manner. IL-10
also contributed to Treg generation, but to a lesser
extent. Our data are consistent with a recent study,
which showed that CD1031 regulatory DCs migrated
from the lamina propria to the mesenteric lymph nodes
to present locally administered antigen to naive CD41
T cells and drive the differentiation of Tregs in a TGF-
b-mediated manner.28 Nevertheless, other groups also
reported DCs promote Tregs through activation of reti-
noid acid and production of indoleamine 2, 3-dioxyge-
nase.18,29 All these data demonstrate the important
regulatory properties of regulatory DCs.
Several studies demonstrated previously that MSCs
might interfere with the differentiation of CD341
HPC into mature DCs.11,12 Recently, Li et al.30 showed
that human bone marrow-derived MSCs may induce
HPCs to generate regulatory DCs through activation of
the Notch pathway. Liu et al.11 reported that embryonic
fibroblast-derived MSCs induced generation of mouse
regulatory DCs from HPCs by activation of SOCS3 in
a IL-10-dependent manner. In contrast to previous
studies, we demonstrated that MSCs induce differentia-
tion of circulating CD11c1B2202 DC precursors into
regulatory DCs. Additionally, we identified that it was
the differentiation of DC precursors to immature DCs,
rather than differentiation of immature DCs to mature
DCs, that was required for generation of regulatory
DCs. This is important for understanding the ontogeny
of regulatory DCs and for generating large numbers of
regulatory DCs for immunotherapy.
We also performed splenectomy to determine
whether splenic immune response contributes to
MSC-induced protection against liver injury. Surpris-
ingly, MSCs are still efficacious in ameliorating FHF
in splenectomized mice. There is no change in DC
precursors, regulatory DCs, Tregs in the liver, or serum
levels of TNF-a and IFN-c. Migration and residence
of MSCs in the liver are also unaffected as compared
to sham controls (data not shown). It is known that
the white pulp of the spleen consists of aggregates of
lymphoid tissue, which can identify antigens and
mount an immune response to antigens within the
blood, and thus plays a vital role in immune homeo-
statics and fighting infections.31,32 However, in the
current model it seems that splenic immune response
is redundant to MSC-mediated attenuation of
bacteria-induced FHF. Our results are concordant with
previous study which demonstrated the importance of
hepatic local DC-T cell interaction in the liver
injury,13 and further strengthen the concept that sup-
pression of immune response in the hepatic microen-
vironment by MSCs is essential for the treatment
effects on FHF in mice.
MSCs have been shown to exert their immunoregu-
latory effects through secretion of soluble factors such
as PGE2 and indoleamine 2,3-dioxygenase.
5 Recently,
several studies showed that when cultured in the pres-
ence of PGE2, DCs have a lower capacity to present
antigens to T cells, and they produce lower levels of
IL-12 and higher levels of IL-10 or arginase-1.33,34 We
demonstrated that MSC-derived PGE2 is responsible
for the generation of CD11c1MHCIIhiCD80loCD86lo
regulatory DCs from CD11c1B2202 DC precursors.
Moreover, we showed that this process is mediated by
EP4, which is the receptor of PGE2, and subsequent
activation of PI3K/ERK1/2 pathway. Thus, our data
provide new evidence to demonstrate the importance
of PGE2 and related downstream pathways in MSC-
mediated immunoregulatory function.
It is of interest to elucidate the role of Th1 response
in the pathogenesis of P. acnes-induced liver injury.
Although appropriate Th1 cell traffic into the inflamed
liver is necessary to eliminate microorganisms,14 exces-
sive influx of Th1 cells may cause more severe inflam-
mation.13 Thus, the final outcome of T-cell-mediated
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disease is dependent on the extent and duration of
effector T-cell recruitment into the target tissue. We
found that modulation of Th1 response by MSCs
accelerated the elimination of bacteria in the liver,
reduced inflammatory infiltration, and improved liver
functions in the long run. Thus, MSCs may down-
regulate excessive Th1 response, retain a certain extent
of Th1 capability, and enable the host to eradicate an
invading pathogen with minimum tissue damage.
Notably, administration of MSCs led to a marked
reduction of DNA copies of P. acnes in the liver 1 day
after bacterial priming. Since 24 hours after bacterial
injection may not be enough for the generation of an
efficient Th1 response, Th1 cells are unlikely to medi-
ate the reduction of P. acnes DNA copies at this stage.
MSCs are able to activate macrophages through a
direct physical cell-to-cell interaction and secretion of
cytokines such as IL-6 and GM-CSF.35,36 Kupffer cells
are specialized macrophages that can phagocytose and
degrade pathogenic bacteria through formation of
phagolysosomes. It is possible that MSCs can augment
the capability of Kupffer cells in the liver, leading to
an accelerated clearance of P. acnes early after priming.
Our data demonstrated that MSC treatment is ther-
apeutic for granulomatous hepatitis and ConA-induced
FHF, and is preventive for the P. acnes plus LPS-
induced FHF model. This is consistent with results
from a recent study showing that MSC-conditioned
medium was able to ameliorate D-galactosamine-
induced FHF by inhibiting hepatocellular death and
stimulating hepatocyte regeneration.37 More impor-
tant, MSCs transplantation showed favorable short-
term efficacy in patients with liver failure.38 Finally,
allogeneic MSCs are able to induce regulatory DCs in
the host to exert immunoregulatory functions, which
is of significance for clinical application of allogeneic
MSCs in treatment of FHF.
In conclusion, the current study shows that MSC-
based therapy has profound inhibitory effects on
inflammatory responses and that it ultimately improves
survival in mice undergoing P. acnes plus LPS-induced
FHF. Furthermore, we demonstrate direct induction of
CD11c1MHCIIhiCD80loCD86lo regulatory DCs
from CD11c1B2202 DC precursors both in vivo and
in vitro. This work shows that MSCs induce an inte-
grated response to liver disease and further lays a solid
foundation for application of MSCs in the treatment
of this devastating disorder.
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